The short answer
Small randomized studies have reported changes in measures such as fine wrinkles, roughness, elasticity or hydration after selected polynucleotide formulations. That is a real signal—but not proof that every PN/PDRN product works, that one formulation is superior to HA, or that results last for a fixed period.
Before considering treatment, identify the exact material, concentration, other ingredients, registered indication, source, injection area and doctor. “Salmon DNA facial” is a slogan, not a product specification.
PN, PDRN and hybrid products
PN usually refers to purified polynucleotide chains used in an injectable gel. PDRN is commonly used for a related mixture of DNA-derived fragments. In aesthetic marketing, however, the terms are often blurred. Products can differ in chain characteristics, concentration, viscosity, source material, purification and whether HA or another ingredient is added.
That difference affects how a product behaves in tissue and what evidence applies. A study of a PN gel around the eyes cannot validate a different PDRN solution, a PN-HA hybrid or a full-face injection protocol. Do not let a shared ingredient family erase formulation differences.
What human studies show
One randomized, double-blind, split-face trial compared a PN filler with an HA product around the eyes. Both sides changed over time; the PN side showed higher improvement rates in some measures such as elasticity, hydration, roughness and pore volume, while dermal-density change was not significantly different. The study was limited to its products, area, participants and follow-up.
Open-label cohorts have also reported improvement, but without a blinded control group they are more vulnerable to selection, measurement and expectation bias. This is why product-specific randomized evidence should carry more weight than broad claims based on uncontrolled before-and-after observations.
What the evidence cannot establish
- Which PN or PDRN formulation is most effective
- A universal treatment schedule or maintenance interval
- Long-term outcomes after repeated courses over years
- Safety during pregnancy or breastfeeding
- Superiority over sunscreen, topical treatment, HA, lasers or other procedures for every concern
- That laboratory findings translate into “repairing your DNA” in facial skin
Many aesthetic studies are small, short and product-associated. Outcomes may include investigator or patient ratings rather than a clinically meaningful comparison. A statistically significant change also may not be large enough to matter to every person.
Under-eye and full-face use
The under-eye area is not just thin skin. A visible hollow can come from bone and fat structure, a dark circle from pigment or vessels, and puffiness from fluid or fat pads. A skin-quality injectable cannot be assumed to correct all of them. Multiple superficial papules and swelling are expected parts of some injection techniques, but persistent lumps, colour change or eye symptoms are not something to diagnose online.
Full-face “glow” protocols also vary in concentration, amount, needle depth and number of entry points. Evidence from the eye area should not be copied to the whole face without a product-specific rationale. If the concern is volume or contour, read our skin booster vs filler vs biostimulator comparison.
Risks and uncertainty
Common short-term injection effects can include pain, redness, swelling, bruising, itching and small raised injection points. Infection, inflammatory reactions, persistent nodules, allergy and unintended placement require medical assessment. Facial injection also involves vascular anatomy; a clinic should not claim “zero occlusion risk” merely because a product is marketed as non-volumizing.
Some products use fish-derived raw material, but source and purification vary. Ask about the exact product and disclose relevant allergies rather than assuming that every PN/PDRN injectable has the same source or risk. Do not inject through active infection, inflamed acne or a damaged skin barrier.
Severe or rapidly increasing pain, pale or mottled skin, visual change, eye pain, breathing difficulty, widespread hives or rapid swelling of the lips or tongue requires urgent medical care.
Verify the exact product
Regulatory status is country-, product- and indication-specific. A European mark, Korean approval or published trial does not establish Thai FDA registration. Search the exact Thai product name and registration number, then make sure the sealed syringe and Thai label match what was promised.
- Photograph the box, Thai label and lot number
- Check expiry date and storage before opening
- Ask the doctor to state every active component, not only “PN”
- Keep the injection map, amount and date for future care
- Confirm who imports and can trace the product if a problem occurs
Questions before treatment
- Is this PN, PDRN, HA-PN or another combination?
- Which human trial studied this exact product and treatment area?
- What change will be measured—hydration, fine lines, texture or volume?
- Which findings would mean the treatment has not matched my diagnosis?
- What side effects are expected, and what symptoms require same-day contact?
- Who performs the injection and manages delayed reactions?
- What remains in the skin, and can any component be dissolved?
Do not buy a long course before seeing how the diagnosis, product authenticity and follow-up system are explained.
The bottom line
PN/PDRN injections have some human evidence for selected skin-quality outcomes, but the evidence is not one uniform verdict. Product, formulation, area and protocol matter, long-term comparative data remain limited, and “DNA repair” is not an appropriate clinical promise. Verify the exact Thai-registered product and choose a licensed doctor who can explain both the measured goal and the complication plan.